Загрузка...
Population Pharmacokinetics of Brentuximab Vedotin in Adult and Pediatric Patients With Relapsed/Refractory Hematologic Malignancies: Model‐Informed Hypothesis Generation for Pediatric Dosing Regimens
Prior pharmacokinetic (PK) analyses of the antibody‐drug conjugate (ADC) brentuximab vedotin (1.8 mg/kg every 3 weeks) in pediatric patients with relapsed/refractory hematologic malignancies found that patients aged <12 years exhibited decreased ADC area under the curve (AUC) compared with those...
Сохранить в:
| Опубликовано в: : | J Clin Pharmacol |
|---|---|
| Главные авторы: | , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley and Sons Inc.
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7689911/ https://ncbi.nlm.nih.gov/pubmed/32596842 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1682 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|